^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

FCN-683

i
Other names: FCN-683
Associations
Trials
Company:
Fosun Pharma
Drug class:
Bcl2 inhibitor
Related drugs:
Associations
Trials
over1year
FCN-683, a novel second-generation BCL-2 inhibitor, is highly potent, selective and efficacious against clinically relevant venetoclax-resistant mutations (AACR 2023)
Preferable safety profiles of FCN-683 were shown with no potential hERG inhibitory effect and less drug-drug interaction potential, as evidenced by no inhibitory effect (IC50 >50 μM) on CYP2C9 enzyme compared with VEN (IC50 1.05 μM). Together, FCN-683 is highly potent, selective and highly efficacious against a variety of clinically relevant VEN-resistance BCL-2 mutations in vitro and in vivo and exhibits favorable PK and safety profiles, highlighting its therapeutic potential to become an effective therapeutic approach for VEN-naïve or -resistant BCL-2-addicted B-cell malignancies.
Clinical • IO biomarker
|
BCL2L1 (BCL2-like 1)
|
BCL2 expression • BCL2 mutation • BCL2 G101V
|
Venclexta (venetoclax) • FCN-683